First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
The bull case is simple: analysts see revenue climbing from $802M to $101M as positive interim results from asc22 clinical trials could lead to accelerated regulatory approval.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.